CD274 and lung carcinoma: As the underlying mechanism of intrinsic and acquired resistance to lung cancer chemotherapy or PD-1/PD-L1 blockade therapy was still unclear; only about 20% of patients benefitted from treatment with immune checkpoint inhibitors (19, 20).